.jetcityimage/iStock Editorial through Getty Images Morgan Stanley has chosen Eli Lilly (NYSE: LLY) as its own best biopharma selection for 2025 as well as ranked one more nine names in the room as over weight. The investment financial institution claimed in a details that it continues to feel “diabesity is set to come to be.